Submit Manuscript  

Article Details

Central Nervous System Neoplasms in Hong Kong: An Inscription of Local Studies

[ Vol. 16 , Issue. 3 ]


Jenny K.S. Pu and Dora L.W. Kwong*   Pages 196 - 206 ( 11 )


A registry of brain and central nervous system (CNS) tumor patients in Hong Kong comprising of data from both public and private neurosurgical practices (with approximately 98% patients of Chinese origin), suggested geographical or racial variations in disease incidence. The data confers the finding of a comparatively lower incidence rate of meningioma and malignant gliomas as in other parts of Southeast Asia.

With data suggesting epidemiological difference, the treatment response, particularly in highgrade glioma, was studied. Patients suffering from glioblastoma (GBM) in Hong Kong received the standard of care, which involves safe, maximal resection followed by the Stupp regime. 5-aminolevulinic acid (5-ALA)-based fluorescence-guided surgery was found to be feasible and safe to adopt in the treatment of local WHO Grade III & IV gliomas patients. Survival benefit was seen in a group of patients using extended adjuvant temozolomide (TMZ) treatment for newly diagnosed GBM as compared to those treated with the standard 6 cycles. Salvage therapies with either single agent bevacizumab or bevacizumab plus irinotecan appeared to be effective treatment options in Hong Kong patients with recurrent malignant glioma, with a good associated 6- month progression-free survival (PFS) rate which was comparable to previously published overseas data in this disease type in the same overall population.


Epidemiology, central nervous system, Hong Kong, neurosurgery, extended adjuvant chemotherapy, targeted therapy.


Department of Neurosurgery, Queen Mary Hospital, Hong Kong, Department of Clinical Oncology, Queen Mary Hospital, University of Hong Kong, Hong Kong

Graphical Abstract:

Read Full-Text article